EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European UnionPRNewsWire • 03/05/21
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The LancetPRNewsWire • 03/05/21
Eli Lilly and Company (LLY) Presents at Cowen 41st Annual Health Care Conference - TranscriptSeeking Alpha • 03/04/21
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetesPRNewsWire • 03/04/21
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) TrialPRNewsWire • 03/03/21
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody TherapyGlobeNewsWire • 02/26/21
Eli Lilly says U.S. government has agreed to buy at least 100,000 doses of its COVID antibody therapyMarket Watch • 02/26/21
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19PRNewsWire • 02/26/21
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutionsPRNewsWire • 02/25/21
Lilly Strikes Licensing Deal With Rigel In Push Toward Neurological, Immunological TherapiesBenzinga • 02/18/21
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative DiseasesPRNewsWire • 02/18/21
Eli Lilly's Tirzepatide Reduces A1C And Body Weight, Late-Stage Studies In Type 2 Diabetes ShowBenzinga • 02/17/21
